Small Time Potatoe
@SmallTimePotato
Retired and living the dream. I KILLED $CVM SHORTS and took it from $1 to $41!
You might like
@Stocktwits @howardlindzon The ceo of @Stocktwits said that is ok to call people the R word and spam the site He isn’t concerned about house roles all is concerned about is his pocketbook look below
$IMMX just delivered one of the most stunning data drops at #ASH2025 🚀 NXC-201 posted a 75% CR rate in relapsed/refractory AL Amyloidosis — with potential to hit ~95% CR as pending patients read out. Clean safety. Organ responses. RMAT + Orphan. This isn’t incremental — this…
immixbio.com
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing...
- NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee - - In four out of five pending patients, MRD negativity in bone marrow...
$IMMX just closed a $100M upsized offering at $5.10 — institutions drew a line in the sand. 🚀 This gives IMMX runway into 2027, right as ASH data hits. Smart money wanted in before the catalyst. Big cash. Big confidence. Big moment ahead. 🔬🔥 immixbio.com/immix-biopharm…
immixbio.com
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and...
LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in relapsed/refractory AL Amyloidosis, today announced the...
$IMMX At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results,Advancing Toward BLA Submission as a Potentially First- +Best-in-Class Therapy for relapsed/refractory AL Amyloidosis • BioPharmCatalyst @BiotechPort biopharmcatalyst.com/company/IMMX/n…
The bispecifics are half of the efficacy (till now at least), nasty safety profile and chronic treatment. I am not sure anyone is seriously developing bispecifics in this indication. $IMMX should be approved next year.
$IMMX still looks better to me. Bispecific needs 24 cycles monthly injections. Also, it is not clear to me if AbbVie is pushing for approval in rr AL. Will be interesting to compare the safety
$IMMX dropped its #ASH25 data first… and only after investors saw it did the company price a $100M UPSIZEDoffering at $5.10. 🔥 Upsized after data = real demand. Funds reviewed the results and said: “We want MORE at this price.” That’s conviction, not dilution. 🚀🧬
$IMMX delivers its biggest data day today NEXICART-2 readout: • 95% normalized markers in ≤14 days • 14/16 MRD-negative by Day 25 • Cardiac/renal/hepatic responses • Zero neurotox • 19/20 in VGPR/CR Plus new ASH BCMA-CAR T autoimmune data validating the…
$IMMX isworthlong−termfocus.Marketcap 139.35M on Dec 3, P/B 16.86—higher than industry avg 4.54, but 5-yr capex growth 176%. Premium backed by R&D, focus on tracking.🚀🚀🚀 $MSTR $MU $AAPL $SNDK $COIN $AMZN $AVGO #STOCKS #StocksToWatch #AEWDynamite
🚨 $IMMX just dropped a new slide, not in Corp deck NXC-201 now framed as a plasma cell–targeting platform for autoimmune: lupus, MG, RA, more. #ASH25 still about AL, but the pivot is clear. Low IL-6 Outpatient CAR-T Huge potential
$immx Wow! Monday it is, I guess. Only two more training days and then we ride boys
Great new podcast here featuring @Immixbiopharma!!! Definitely one to keep an eye on!!! 🧬🧬🧬 $IMMX youtu.be/R7prawxnVoU
Great new podcast here featuring @Immixbiopharma!!! Definitely one to keep an eye on!!! 🧬🧬🧬 $IMMX youtu.be/R7prawxnVoU
$IMMX holding up above $4.50 with solid tape and 22M+ volume. Watching this one for strength above recent intraday resistance.
$immx I encourage all to listen both conference webcasts from this week “The cash (on hand) will take us thru end of trial, AND thru FDA feedback on the BLA we are submitting. We are in a great place financially” BLA filed 1H26 Efficacy and durability updated at #ASH25…
$IMMX AZ new AL amyloidosis CAR-T trial hasn’t even started recruiting. IMMX already has U.S. patients treated, early efficacy, and an ASH oral. AZ is concept stage. IMMX is clinical stage. The gap isn’t months — it’s years. First-mover advantage is real. #ASH25…
$immx It’s a BUY Immix flagged early signs in its AL amyloidosis CAR-T program, but an upcoming ORAL data presentation at ASH and low valuation prompt the analyst to reaffirm a BUY. #ASH25 seekingalpha.com/article/483947…
$IMMX For all interested in @Immixbiopharma , please know they have plenty of cash. In fact, they have a ton of it. 🔥There is no financing risk🔥 See attached for breakdown and sources for all data points
$Immx dropped a compelling ASH Oral abstract today Their CAR-T data in AL Amyloidosis shows deep, durable responses with a favorable safety profile. 🔥For a microcap to land an Oral at ASH is rare🔥 One to watch as cell therapy expands beyond oncology. #ASH2025 Abstract…
$immx will be presenting w some heavy weights. This is a high-signal session for: • Competitive landscape in AL amyloidosis • CAR-T encroaching into plasma-cell & amyloid space • Durability vs depth MRD debate • Organ-specific outcomes (renal, cardiac) Not many small…
United States Trends
- 1. Brook Lopez 2,940 posts
- 2. Keyonte George 2,655 posts
- 3. #SmackDown 27.8K posts
- 4. Kwanzaa 58.1K posts
- 5. Kawhi 4,985 posts
- 6. UTSA 4,322 posts
- 7. Nick Shirley 163K posts
- 8. Somaliland 155K posts
- 9. Melo 12.5K posts
- 10. FDNY 15.3K posts
- 11. Blazers 3,372 posts
- 12. Jazz 26.6K posts
- 13. Embiid 5,197 posts
- 14. Dizzy 8,942 posts
- 15. #Ashes 21.2K posts
- 16. Jordan Poole N/A
- 17. Cade 21.8K posts
- 18. Patton 3,811 posts
- 19. Maxey 2,892 posts
- 20. Justified 16.8K posts
You might like
-
European Mathematical Society
@euromathsoc -
Kora Reddy
@paststat -
Olga Morales
@AstroGann33 -
Hspooner
@Hspooner665 -
Alan Hammond
@alanhammond_ -
Stefanie Kammerman/The Stock Whisperer
@VolumePrintcess -
Matt Busigin
@mbusigin -
Dave Kranzler
@InvResDynamics -
ATLnsider
@ATLnsider -
eld
@eldtrades -
Bullish Bears
@bullishbrs -
Walk The Walk
@WalktheWalk -
Greg Speicher
@Greg_Speicher -
Emmanuele
@Biotech2050 -
Mister Buyside
@MisterBuyside
Something went wrong.
Something went wrong.